EyePoint
EYPT
ATLANTA, GA – – (Globe Newswire – November 18, 2026) – – A shareholder class action lawsuit has been filed against EyePoint, Inc. (“EyePoint”) (NASDAQ: EYPT). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) DURAVYU was less effective than Defendants had led investors to believe; (ii) accordingly, DURAVYU’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you purchased EyePoint shares between May 27, 2025 and August 14, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/eyepoint/ for more information.
The deadline to ask the court to be appointed lead plaintiff in the case is January 19, 2027.
Registration Deadline
Lead Plaintiff Deadline Has Passed
January 19, 2027